{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_Display\ Name in Display Name (approximate match)
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103189
(2009)
Source URL:
First approved in 2009
Source:
BLA103189
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
US Approved Rx
(2011)
Source:
ANDA091449
(2011)
Source URL:
First approved in 1995
Source:
NDA020597
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Latanoprost (free acid) is a metabolite of latanoprost which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester prodrug which is converted to the Latanoprost-acid by endogenous esterase enzymes. The free acid is pharmacologically active and is 200 times more potent than latanoprost as an agonist of the human recombinant Prostaglandin F receptor. However, the free Latanoprost-acid is more irritating and less effective than Latanoprost when applied directly to the eyes of human glaucoma patients.
Status:
US Approved Rx
(2011)
Source:
ANDA091449
(2011)
Source URL:
First approved in 1995
Source:
NDA020597
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Latanoprost (free acid) is a metabolite of latanoprost which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester prodrug which is converted to the Latanoprost-acid by endogenous esterase enzymes. The free acid is pharmacologically active and is 200 times more potent than latanoprost as an agonist of the human recombinant Prostaglandin F receptor. However, the free Latanoprost-acid is more irritating and less effective than Latanoprost when applied directly to the eyes of human glaucoma patients.
Status:
US Approved Rx
(2011)
Source:
ANDA091449
(2011)
Source URL:
First approved in 1995
Source:
NDA020597
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Latanoprost (free acid) is a metabolite of latanoprost which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester prodrug which is converted to the Latanoprost-acid by endogenous esterase enzymes. The free acid is pharmacologically active and is 200 times more potent than latanoprost as an agonist of the human recombinant Prostaglandin F receptor. However, the free Latanoprost-acid is more irritating and less effective than Latanoprost when applied directly to the eyes of human glaucoma patients.
![Structure of Sodium 2-[[4-[(2-chlorobenzyl)ethylamino]-m-tolyl]azo]benzothiazole-6-sulfonate](/img/32fe5d0b-50b0-4f82-9588-121d04849022.svg?size=200&context=xohyvkusel)
![Structure of ALTERNATIVE DEFINITION for [5'-GUANOSINE-M-RNA-CAP-1-3'-PHOSPHATE]](/img/3a2bab4e-1b15-4b2c-944e-56a9bc3582d5.svg?size=200&context=xohyvkusel)
